372 related articles for article (PubMed ID: 29962308)
1. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
[TBL] [Abstract][Full Text] [Related]
5. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program.
Tang Y; Horvitz-Lennon M; Gellad WF; Lave JR; Chang CH; Normand SL; Donohue JM
Psychiatr Serv; 2017 Jun; 68(6):579-586. PubMed ID: 28196460
[TBL] [Abstract][Full Text] [Related]
6. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.
Kreyenbuhl JA; Valenstein M; McCarthy JF; Ganoczy D; Blow FC
Psychiatr Serv; 2007 Apr; 58(4):489-95. PubMed ID: 17412850
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH
J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.
Gilmer TP; Dolder CR; Folsom DP; Mastin W; Jeste DV
Psychiatr Serv; 2007 Jul; 58(7):1007-10. PubMed ID: 17602020
[TBL] [Abstract][Full Text] [Related]
10. National trends in psychotropic medication polypharmacy in office-based psychiatry.
Mojtabai R; Olfson M
Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
[TBL] [Abstract][Full Text] [Related]
11. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
12. Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study.
Boskailo E; Malkoc A; McCurry DB; Venter J; Drachman D; Ramos GM
Acta Med Acad; 2017 Nov; 46(2):133-144. PubMed ID: 29338277
[TBL] [Abstract][Full Text] [Related]
13. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
14. Off-label use of antipsychotic medications in Medicaid.
Leslie DL; Rosenheck R
Am J Manag Care; 2012 Mar; 18(3):e109-17. PubMed ID: 22435962
[TBL] [Abstract][Full Text] [Related]
15. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
16. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study.
Kroken RA; Johnsen E; Ruud T; Wentzel-Larsen T; Jørgensen HA
BMC Psychiatry; 2009 May; 9():24. PubMed ID: 19445700
[TBL] [Abstract][Full Text] [Related]
17. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
[TBL] [Abstract][Full Text] [Related]
18. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
19. Geographic and clinical variation in clozapine use in the United States.
Stroup TS; Gerhard T; Crystal S; Huang C; Olfson M
Psychiatr Serv; 2014 Feb; 65(2):186-92. PubMed ID: 24233347
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy.
Fisher MD; Reilly K; Isenberg K; Villa KF
BMC Psychiatry; 2014 Nov; 14():341. PubMed ID: 25433495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
